Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Neoleukin Therapeutics

Neoleukin Therapeutics
PUBLIC STATUS
1-10 EMPLOYEES
NLTX STOCK SYMBOL
1 INVESTMENTS
$10.56 SHARE PRICE (As of Friday Closing)
Description

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. It generates immunotherapies using de novo protein design technology. The firm uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises of NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Discovery Tools (Healthcare)
Stock Exchange
NAS
Primary Office
  • 401 Terry Avenue North
  • Seattle, WA 98109
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Neoleukin Therapeutics’s full profile, request a free trial.

Neoleukin Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.18 - $13.43 $513M $10.46 -$2.71 536K 48.6M

Neoleukin Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 7,918 (35,880) 156,290 240,806
Revenue 0 25,000 0 0
EBITDA (67,972) (33,144) (51,177) (37,620)
Net Income (66,228) (31,585) (50,183) (37,002)
Total Assets 69,791 77,618 110,329 154,380
Total Debt 616 6 33 47
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Neoleukin Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Neoleukin Therapeutics‘s full profile, request access.

Request full access to PitchBook

Neoleukin Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 09-Aug-2019 000000000000000000 Drug Discovery 00000000 00000000 00
To view this company’s complete investment and acquisition history, request access »

Neoleukin Therapeutics Executive Team (6)

Name Title Board
Seat
Contact
Info
Jonathan Drachman MD Chief Executive Officer & Chairman
Kamran Alam Chief Financial Officer
Barbara Troupin MD Chief Medical Officer & Vice President
Daniel-Adriano Silva Ph.D Vice President
Umut Ulge Vice President

1 Former Executive

You’re viewing 5 of 6 executives. Get the full list »

Neoleukin Therapeutics Board Members (6)

Name Representing Role Since Contact
Info
Cantey Boyd Self Board Member 000 0000
Jonathan Drachman MD Neoleukin Therapeutics Chief Executive Officer & Chairman 000 0000
Lewis Williams Ph.D Neoleukin Therapeutics Board Member 000 0000
Sarah Noonberg MD Self Board Member 000 0000
Sean Nolan Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »